Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts. On September 2, 2022, Allena Pharmaceuticals, Inc., filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware.
P/B ratio for Allena Pharmaceuticals, Inc. (ALNAQ)
P/B ratio as of 2021: 1.02
According to Allena Pharmaceuticals, Inc.'s latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 1.02. At the end of 2020 the company had a P/B ratio of 1.84.
P/B ratio history for Allena Pharmaceuticals, Inc. from 2015 to 2021
P/B ratio at the end of each year
| Year | P/B ratio |
|---|---|
| 2021 | 1.02 |
| 2020 | 1.84 |
| 2019 | 3.52 |
| 2018 | 2.29 |
| 2017 | 0.55 |
| 2016 | -2.57 |
| 2015 | -4.36 |